- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03642132
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)
Study Overview
Status
Conditions
Detailed Description
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, international, multi-center, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). The primary endpoint is progression-free survival (PFS) as determined based on blinded independent central review (BICR) assessment per RECIST v1.1.
On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study. The alliance has notified health authorities and trial investigators of the decision to discontinue the trial. The decision was based on several emerging factors since the trial's initiation, including the previously announced interim results from JAVELIN Ovarian 100 study (B9991010), which was stopped due to futility of efficacy at a planned interim analysis on 21 December 2018. The alliance determined that the degree of benefit observed with avelumab in frontline ovarian cancer in that study does not support continuation of the JAVELIN Ovarian PARP 100 trial in an unselected patient population and emphasizes the need to better understand the role of immunotherapy in ovarian cancer. Additional factors include the rapidly changing treatment landscape and the approval of a PARP inhibitor in the frontline maintenance setting. The decision to discontinue the JAVELIN Ovarian PARP 100 trial was not made for safety reasons.
Patients who remain in the study will continue receiving investigational products according to their randomized treatment assignment and will be monitored for appropriate safety assessments until treatment discontinuation.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Epworth Foundation trading as Epworth HealthCare
-
Richmond, Victoria, Australia, 3121
- Epworth HealthCare, Clinical Trials & Research Centre
-
-
-
-
-
Namur, Belgium, 5000
- CHU-UCL Namur/Site Sainte Elisabeth
-
-
-
-
-
Cork, Ireland, T12 DV56
- Bon Secours Hospital
-
-
-
-
MI
-
Milano, MI, Italy, 20141
- Istituto Europeo di Oncologia (IEO)
-
-
RM
-
Roma, RM, Italy, 00168
- Fondazione Policlinico Universitario A. Gemelli IRCCS
-
-
-
-
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 06273
- Gangnam Severance Hospital
-
Seoul, Korea, Republic of, 06351
- Clinical Trial Pharmacy, Samsung Medical Center
-
Seoul, Korea, Republic of, 06229
- Gangnam Severance Hospital
-
-
-
-
-
Moscow, Russian Federation, 121309
- Limited Liability Company "VitaMed" (LLC "VitaMed")
-
-
-
-
-
Singapore, Singapore, 169610
- National Cancer Centre Singapore
-
Singapore, Singapore, 188770
- Raffles Hospital
-
Singapore, Singapore, 169608
- Singhealth Investigational Medicine Unit
-
Singapore, Singapore, 188770
- Raffles Radiology
-
Singapore, Singapore, 169608
- Department of Nuclear Medicine and Molecular Imaging
-
Singapore, Singapore, 169856
- Department of Pathology
-
Singapore, Singapore, 217562
- Farrer Park Hospital
-
-
-
-
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 112
- Koo Foundation Sun Yat-Sen Cancer Center
-
Taipei, Taiwan, 112
- Department of Radiology, Koo Foundation Sun Yat-Sen Cancer Center
-
Taipei, Taiwan, 112
- Division of Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Arizona Oncology Associates, PC - HAL
-
Phoenix, Arizona, United States, 85027
- Arizona Oncology Associates, PC - HAL
-
Scottsdale, Arizona, United States, 85258
- Arizona Oncology Associates, PC - HAL
-
Tempe, Arizona, United States, 85284
- Arizona Oncology Associates, PC - HAL
-
Tucson, Arizona, United States, 85711
- Arizona Oncology Associates, PC - HOPE
-
Tucson, Arizona, United States, 85704
- Arizona Oncology Associates, PC - HOPE
-
-
California
-
Santa Barbara, California, United States, 93105
- Sansum Clinic
-
Solvang, California, United States, 93463
- Sansum Clinic
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Smilow Cancer Hospital at Yale-New Haven
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
Bronx, New York, United States, 10461
- Montefiore Medical Center - EPC
-
Bronx, New York, United States, 10461
- Montefiore Medical Center, Department of Obstetrics and Gynecology and Women's Health
-
Bronx, New York, United States, 10467
- Montefiore Medical Center-Centennial Facility
-
Mineola, New York, United States, 11501
- NYU Winthrop Hospital, Gynecologic Oncology
-
Mineola, New York, United States, 11501
- NYU Winthrop Hospital, Infusion Center
-
Mineola, New York, United States, 11501
- NYU Winthrop Radiology
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Oncology Hematology Care, Inc.
-
Cincinnati, Ohio, United States, 45211
- Oncology Hematology Care, Inc.
-
Cincinnati, Ohio, United States, 45230
- Oncology Hematology Care Inc
-
Cincinnati, Ohio, United States, 45236
- Oncology Hematology Care Inc
-
-
Oregon
-
Portland, Oregon, United States, 97227
- Northwest Cancer Specialists, P.C.
-
Portland, Oregon, United States, 97213-2982
- Northwest Cancer Specialists, P.C.
-
Portland, Oregon, United States, 97225
- Northwest Cancer Specialists, P.C.
-
Tualatin, Oregon, United States, 97062
- Northwest Cancer Specialists, P.C.
-
-
Tennessee
-
Dickson, Tennessee, United States, 37055
- Tennessee Oncology, PLLC
-
Franklin, Tennessee, United States, 37067
- Tennessee Oncology, PLLC
-
Gallatin, Tennessee, United States, 37066
- Tennessee Oncology, PLLC
-
Hermitage, Tennessee, United States, 37076
- Tennessee Oncology, PLLC
-
Lebanon, Tennessee, United States, 37090
- Tennessee Oncology, PLLC
-
Murfreesboro, Tennessee, United States, 37129
- Tennessee Oncology, PLLC
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC
-
Nashville, Tennessee, United States, 37203
- The Sarah Cannon Research Institute
-
Nashville, Tennessee, United States, 37205
- Tennessee Oncology, PLLC
-
Nashville, Tennessee, United States, 37207
- Tennessee Oncology, PLLC
-
Nashville, Tennessee, United States, 37211
- Tennessee Oncology, PLLC
-
Shelbyville, Tennessee, United States, 37160
- Tennessee Oncology, PLLC
-
Smyrna, Tennessee, United States, 37167
- Tennessee Oncology, PLLC
-
-
Texas
-
Bedford, Texas, United States, 76022
- Texas Oncology Bedford
-
Fort Worth, Texas, United States, 76104
- Texas Oncology
-
Irving, Texas, United States, 75063
- US Oncology Investigational Products Center
-
Irving, Texas, United States, 75063
- US Oncology Investigational Products Center (IPC)
-
San Antonio, Texas, United States, 78240
- Texas Oncology- San Antonio
-
-
Virginia
-
Chesapeake, Virginia, United States, 23320
- Virginia Oncology Associates
-
Norfolk, Virginia, United States, 23502
- Virginia Oncology Associates
-
Virginia Beach, Virginia, United States, 23456
- Virginia Oncology Associates
-
-
Washington
-
Vancouver, Washington, United States, 98684
- Northwest Cancer Specialists, P.C.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed Stage III IV epithelial ovarian, fallopian tube, or primary peritoneal cancer including carcinosarcoma with high-grade serous component.
- Patients must be candidates for bevacizumab in combination with platinum based chemotherapy and previously untreated.
Must have completed a primary surgical debulking procedure, or be candidates for neoadjuvant chemotherapy with planned interval debulking surgery.
- Patients who completed primary debulking must have had incompletely resected disease that is macroscopically/grossly visible and at least with lesions >1 mm and be randomized at a maximum of 8 weeks after surgery.
For patients who are candidates for neoadjuvant chemotherapy, the diagnoses must have been confirmed by:
- Core tissue (not fine-needle aspiration) biopsy is required for diagnosis.
- Stage IIIC-IV documented via imaging or surgery (without attempt at cytoreduction).
- Serum CA-125/CEA ratio >25. If the serum CA-125/CEA ratio is <25, then workup should be negative for the presence of a primary gastrointestinal or breast malignancy (<6 weeks before start of neoadjuvant treatment).
- Randomization must occur within 8 weeks after diagnosis.
- Availability of an archival FFPE tumor tissue block or a minimum of 25 slides, together with an accompanying original H&E slide. If archived FFPE tissue is not available, a de novo (ie, fresh) tumor sample must be obtained in accordance with local institutional practice for tumor biopsies. Tumor tissue must contain 40% or greater tumor nuclei per central laboratory assessment.
- ECOG performance status 0-1
- Age >=18 years (or >=20 years in Japan).
- Adequate bone marrow, hepatic, and renal function and blood coagulation
Exclusion Criteria:
- Non-epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors.
- Patients for whom intraperitoneal cytotoxic chemotherapy is planned.
- Prior exposure to immunotherapy with interleukin (IL)-2, interferon alpha (IFN-α), or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte associated antigen 4 (anti-CTLA4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, excluding therapeutic anticancer vaccines.
- Prior treatment with a PARP inhibitor.
- Prior treatment with any anti-vascular endothelial growth factor (VEGF) drug, including bevacizumab.
- Major surgery (other than debulking or exploratory surgery for ovarian cancer) for any reason within 4 weeks prior to randomization and/or incomplete recovery from surgery.
- Prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
- Prior targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their ovarian, peritoneal primary or fallopian tube carcinoma.
- Prior organ transplantation including allogenic stem cell transplantation.
- Diagnosis of Myelodysplastic Syndrome (MDS).
- Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: chemotherapy, avelumab and talazoparib
Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
|
Chemotherapy Period Paclitaxel Carboplatin Avelumab Maintenance Period Avelumab Talazoparib |
Experimental: chemotherapy, and talazoparib
Platinum-based chemotherapy followed by talazoparib maintenance
|
Chemotherapy Period Paclitaxel Carboplatin Maintenance Period Talazoparib |
Active Comparator: chemotherapy and bevacizumab
Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
|
Chemotherapy Period Paclitaxel Carboplatin Bevacizumab Maintenance Period Bevacizumab |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (Participants With Newly Diagnosed Advanced Ovarian Cancer With Defects in DDR+)
Time Frame: At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by Blinded Independent Central Review (BICR) regardless of initiation of new anti-cancer therapy
|
Progression-free survival (PFS) was defined as the time from randomization to the date of the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first.
PD: >=20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study.
In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5mm, appearance of one or more new lesions was considered PD.
|
At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by Blinded Independent Central Review (BICR) regardless of initiation of new anti-cancer therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (On-Treatment Period)
Time Frame: From the first dose of study treatment through up to 30 days after minimum last dose of study treatment or start day of new anti-cancer drug therapy minus 1 day (maximum up to 3.5 years approximately)
|
An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death, was lifethreatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event. AEs included SAEs and non-serious AEs. On-treatment period was defined as the time from the first dose of study treatment through up to 30 days after minimum last dose of study treatment or start day of new anti-cancer drug therapy minus 1 day. |
From the first dose of study treatment through up to 30 days after minimum last dose of study treatment or start day of new anti-cancer drug therapy minus 1 day (maximum up to 3.5 years approximately)
|
Number of Participants With ADA Against Avelumab by Never and Ever Positive Status
Time Frame: Day 1 pre-dose of Cycles 1, 2, 3, and 4 in the chemotherapy period and Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period and at the end of treatment/withdrawal, up to 27 months.
|
Predose Anti-drug antibodies (ADA) samples were collected within 2 hours prior to avelumab dosing and drawn from the contralateral arm of the avelumab infusion.
|
Day 1 pre-dose of Cycles 1, 2, 3, and 4 in the chemotherapy period and Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period and at the end of treatment/withdrawal, up to 27 months.
|
Pre-dose/Trough Concentration (Ctrough) for Avelumab (Chemotherapy Period)
Time Frame: Day 1 of Cycles 1, 2, 3, and 4 in the chemotherapy period (1 cycle = 3 weeks)
|
Ctrough was defined as predose concentration during multiple dosing and it was observed directly from data
|
Day 1 of Cycles 1, 2, 3, and 4 in the chemotherapy period (1 cycle = 3 weeks)
|
Pre-dose/Trough Concentration (Ctrough) for Avelumab (Maintenance Period)
Time Frame: Pre-dose on Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period (1 cycle = 6 weeks) and at the end of treatment, up to 27 months.
|
Ctrough was defined as predose concentration during multiple dosing and it was observed directly from data
|
Pre-dose on Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period (1 cycle = 6 weeks) and at the end of treatment, up to 27 months.
|
Cmax for Avelumab (Chemotherapy Period)
Time Frame: Day 1 of Cycles 1, 2, 3, and 4 in the chemotherapy period (1 cycle = 3 weeks)
|
Cmax was defined as maximum observed plasma concentration and it was observed directly from data
|
Day 1 of Cycles 1, 2, 3, and 4 in the chemotherapy period (1 cycle = 3 weeks)
|
Cmax for Avelumab (Maintenance Period)
Time Frame: Day 1 pre-dose of Cycles 1, 2, 3, and 4 in the chemotherapy period and Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period and at the end of treatment/withdrawal, up to 27 months.
|
Cmax was defined as maximum observed plasma concentration and it was observed directly from data
|
Day 1 pre-dose of Cycles 1, 2, 3, and 4 in the chemotherapy period and Days 1 and 29 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 10 in the maintenance period and at the end of treatment/withdrawal, up to 27 months.
|
Ctrough for Talazoprib (Maintenance Period)
Time Frame: Pre-dose on Days 1, 15 and 29 of Cycle 1
|
Ctrough was defined as predose concentration during multiple dosing and it was observed directly from data.
|
Pre-dose on Days 1, 15 and 29 of Cycle 1
|
Overall Survival (Participants of Both DDR+ and Unselected DDR Status)
Time Frame: From 9 weeks up to approximately 3.5 years
|
OS was defined as the time from the date of randomization to the date of death due to any cause.
|
From 9 weeks up to approximately 3.5 years
|
Progression-free Survival (Participants of Unselected DDR Status)
Time Frame: At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by BICR regardless of initiation of new anti-cancer therapy, up to approximately 3.5 years.
|
PFS was defined as the time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occured first.
|
At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by BICR regardless of initiation of new anti-cancer therapy, up to approximately 3.5 years.
|
Progression-free Survival (Participants of Both DDR+ and Unselected DDR Status)
Time Frame: At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by BICR regardless of initiation of new anti-cancer therapy, up to approximately 3.5 years.
|
PFS was defined as the time from randomization to the date of the first documentation of objective progressive disease(PD) or death due to any cause, whichever occured first.
Participants was defined as having defective DDR (DDR+) or having intact DDR (DDR ) using a next generation sequencing based assay method.
|
At screening, 9 and 18 weeks after date of randomization, then every 12 weeks thereafter until PD by BICR regardless of initiation of new anti-cancer therapy, up to approximately 3.5 years.
|
Progression-free Survival on Next-line Therapy. (Participants of Both DDR+ and Unselected DDR Status)
Time Frame: From screening until the participant had objective PD on or prior to start of next-line anti-cancer treatment, and started a second subsequent anti-cancer treatment or the participant died, up to approximately 3.5 years.
|
Progression-free survival on next-line therapy (PFS2) was defined as time from the date of randomization to the start of second subsequent treatment after first documentation of PD, or death from any cause, whichever occured first.
Participants was defined as having defective DDR (DDR+) or having intact DDR (DDR ) using a next generation sequencing based assay method
|
From screening until the participant had objective PD on or prior to start of next-line anti-cancer treatment, and started a second subsequent anti-cancer treatment or the participant died, up to approximately 3.5 years.
|
PFS Per Gynecological Cancer Intergroup Criteria (Participants of Both DDR+ and Unselected DDR Status)
Time Frame: From screening until death, end of study, or participant withdrawal of consent, whichever occurred first, up to approximately 3.5 years.
|
PFS based on investigator assessment per Gynecological Cancer Intergroup criteria (GCIG) would be assessed incorporating both Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and CA 125.
Participants was defined as having defective DDR (DDR+) or having intact DDR (DDR ) using a next generation sequencing based assay method.
|
From screening until death, end of study, or participant withdrawal of consent, whichever occurred first, up to approximately 3.5 years.
|
Functional Assessment of Ovarian Symptom Index-18 (FOSI-18) Score
Time Frame: 3 years
|
NFOSI-18 was an ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. It was specifically designed to be a stand-alone instrument to measure disease-related symptoms, treatment side effects and function/well-being in participants with ovarian cancer. The NFOSI-18 has several subscales: disease-related symptoms physical subscale(9 items), disease-related symptoms emotional subscale(1 item), treatment-related side effect subscale (5 items) and functional well-being (3 items). A high score was good. A score of "0" was a severely symptomatic participant and the highest possible score was an asymptomatic participant. |
3 years
|
Programmed Death Receptor-1 Ligand-1 (PD-L1) Biomarker Expression in Tumor and Immune Cells as Assessed by Immunohistochemistry (IHC) at Baseline
Time Frame: Baseline
|
The number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that were defined by tumor cell morphology and the presence or absence of inflammatory cells
|
Baseline
|
Number of Participants With Mutations in Key Oncogenes at Baseline
Time Frame: Baseline
|
Determination/estimation of the frequency of mutations (total and non-synonymous) present in baseline tumor derived nucleic acid samples and in baseline circulating tumor DNA.
|
Baseline
|
EuroQol Group 5-Dimension 5-Level (EQ-5D-5L) Score
Time Frame: 3 years
|
The EuroQol EQ-5D-5L was a 6 item participant-completed questionnaire designed to assess health status in terms of a single index value or utility score.
There are 2 components to the EQ-5D-5L, a Health State Profile which had individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a Visual Analogue Scale (VAS) in which participants rate their overall health status from 0 (worst imaginable) to 100 (best imaginable).
Published weights were available that allow for imputation of the index score.
Overall index scores ranged from 0 to 1, with low scores representing a higher level of dysfunction.
|
3 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Bevacizumab
- Avelumab
- Talazoparib
Other Study ID Numbers
- B9991030 (Other Identifier: Alias Study Number)
- 2017-004456-30 (EudraCT Number)
- JAVELIN OVARIAN PARP 100 (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on Chemotherapy + avelumab followed by avelumab + talazoparib
-
Centre Francois BaclessePfizerRecruiting
-
Vaccinex Inc.Merck KGaA, Darmstadt, GermanyCompletedCarcinoma, Non-Small-Cell LungUnited States
-
PfizerTerminatedAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsUnited States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
-
Vall d'Hebron Institute of OncologyActive, not recruitingStomach Neoplasms | Gastroesophageal Junction AdenocarcinomaSpain
-
PfizerEMD Serono; Astellas Pharma Inc; Nektar TherapeuticsTerminatedSquamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)Spain, United States, Poland, Belgium
-
Peking Union Medical College HospitalUnknown
-
Peking Union Medical College HospitalUnknown
-
Cancer Institute and Hospital, Chinese Academy...Shanxi Province Cancer Hospital; 307 Hospital of PLA; Qilu Hospital of Shandong... and other collaboratorsUnknownExtranodal Natural Killer/T-Cell Lymphoma, Nasal TypeChina
-
University Hospital, LilleNational Cancer Institute, FranceRecruitingGastric AdenocarcinomaFrance
-
Assiut UniversityUnknown